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“Children are not little adults.” Almost all 
aspects of children’s health including clinical 
trials and drug development are poor cousins 
of adult health. Over the years, pediatricians 
worldwide caution against blind extrapolation 
of adult data to children as it may result in 
considerable harm [1,2]. Also, it is increasingly 
recognized that the roots of many chronic 
diseases in adulthood stem from childhood 
and tackling health issues in children lead to 
improved health in adults [3,4]. Furthermore, 
investment in early childhood has long-term 
benefits in adults not only in health but also 
in other aspects of life such as education and 
crime reduction [4,5]. Arguably, health at 
birth is the single most important predictor 
of health in adulthood as the inequality of an 
infant at birth has intergenerational effects [5]. 
The Carolina Abecedarian Project showed 
that early childhood programs that are of 
high quality result in substantial societal ben-
efits (e.g., reduction of crime, increased earn-
ings, better education) [4,5]. A recent publica-
tion from this project found that this benefit 
also translated into improved adult health 
outcomes [4]. In a randomized trial, Camp-
bell and colleagues described that disadvan-
taged children who were randomized to the 
intervention group (early education, health 
screenings and nutrition program) had sig-
nificantly lower rates of metabolic syndrome, 
obesity and hypertension, when aged in their 
mid-30s, compared with the control group [4].
In specific disease types, although patients 
may be diagnosed with the condition only 
later in life (i.e., in adulthood), many are 
symptomatic from childhood and those with 
earlier onset disease often fare worse [6]. For 
example, severe bronchiectasis in adulthood 
can be prevented by good clinical care 
in childhood before irreversible damage 
occurs [7]. In the respiratory system, the lung 
continues to grow at least till 7–8 years of 
age, if not longer; and the pulmonary immu-
nity and respiratory phenotype is influenced 
by genetic–environmental interactions 
that commence very early in life (possibly 
in utero). There is indeed increasing evidence 
that a substantial proportion of lung disease 
in adults (e.g., chronic obstructive lung dis-
ease and bronchiectasis) has its roots in child-
hood (where it is potentially reversible) [8,9]. 
To reduce the world-wide burden of chronic 
respiratory illness, a greater focus on children’s 
lung and generic health is required [3]. Many, 
if not most of these diseases, are potentially 
modifiable through clinically based 
interventions or are preventable.
Thus not surprisingly, pediatricians 
and clinical researchers repeatedly call for 
increased research relevant to improving the 
health of children. However, funding for pedi-
atric studies falls well short of that for adults. 
In a study that reviewed data on pediatric and 
adult drug trials, Bourgeois and colleagues 
found that, “for the conditions selected, 
59.9% of the disease burden was attributable 
to children, but only 12.0% (292/2440) of 
trials were pediatric (p < 0.001)” [10]. The 
authors tracked all drug trials within a 5‐year 
period and also described that pediatric tri-
als were more reliant on government and 
nonprofit organizations, compared with 
adult-based trials [10].
There are many differences between 
conducting studies in children compared 
“...it is increasingly recognized that the roots of many chronic diseases in adulthood 
stem from childhood and tackling health issues in children lead to improved health 
in adults.”
982 Clin. Invest. (Lond.) (2014) 4(11) future science group
Foreword    Chang & O’Grady
with adults. These range from clinical end points 
to ethical issues. Examples of differences in relevant 
clinical end points are that used in the area of cough, 
the most common symptom in respiratory diseases. In 
adults, cough sensitivity is influenced by gender but in 
prepubertal children, age and not gender influences 
cough sensitivity [11]. The many ethical issues related 
to clinical studies in children include the manner by 
which consent is obtained from parents who act as 
proxies [12], and the possible for very long-term harm. 
Furthermore, trials in older children require not only 
parent consent but also assent from the child, yet there 
are inconsistencies between guidelines on how that 
should be obtained and how to determine capacity to 
consent [13]. These issues become increasingly com-
plex in trials of drugs and vaccines in postmenarche 
females where pregnancy testing and/or contraception 
are required during the study.
The series of articles in this collection focus on vari-
ous broad aspects of clinical trials relevant to children, 
ranging from legislation [14], methodological issues 
relevant to improving clinical trials [15,16] to disease-
specific issues [17–19]. The issue of pediatric exclusive-
ness in clinical trials and financing drug develop-
ment for children has been summarized by Hill and 
colleagues [20]. Auby [14] deliberated relevant legislation 
issues around pharmaceutical research in children. The 
important concept of the placebo effect in pediatric 
studies and its comparison to adults has been reviewed 
by Weimer and Enck [21] and that related to blood sam-
pling in children discussed by Veal [22]. Needham and 
colleagues [16] highlight the initiative in Canada and 
a framework on improving the design, conduct and 
reporting of clinical trials in children. Pavuluri [23] uses 
bipolar disorder to provide an example of the challenges 
in conducting clinical trials in children. Weiss and 
Litonja [15] discusses methodological issues relating to 
clinical trials to prevent and/or treat childhood asthma 
in their paper, focusing on the concept of generaliz-
ability. Ways to improve the efficiency of early trials 
relevant to pediatric oncology were reviewed by Blanco 
and Hargrave [17]. Another article by Hill and col-
leagues [19] highlights the issues of clinically important 
end points relevant to antihypertension agents. Benz 
and colleagues [18] provide an overview of recent trials 
on the treatment of children with frequent relapsing 
syndrome.
This issue highlights some pediatric relevant clini-
cal trials advances and brings clarity to some issues. 
Much more is required for the advancement of pedi-
atric clinical trials so as to improve the health of chil-
dren, particularly those in neglected areas relative 
to burden of disease such as parasitic infections in 
children. We also need to find ways where resource-
rich countries conduct relevant research so as to find 
interventions that can be applied to resource poor 
settings. Given recent data consolidating the impor-
tance of early intervention in preventing disease 
and promoting health, [4,5] a paradigm shift in 
government policies that focuses on early childhood 
(as opposed to the heavy emphasis on adult care) is 
required.
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